Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.

Hims & Hers Health Inc. Class A

In a report released today, Jailendra Singh from Truist Financial reiterated a Hold rating on Hims & Hers Health, with a price target of $27.00. Si...

Hims & Hers Health (HIMS) Receives a Hold from Truist Financial

The latest update is out from Hims & Hers Health ( ($HIMS) ). Hims & Hers Health, Inc. disclosed that Irene Becklund notified the company on July 1...

Hims & Hers Health Announces Accounting Officer Resignation

Hims & Hers Health ( ($HIMS) ) has fallen by -10.19%. Read on to learn why. Hims & Hers Health shares have stumbled this week, falling -10.19% as i...

Hims & Hers Health: Hot Telehealth Darling Hits Turbulence

Analysts fell to the sidelines weighing in on LENZ Therapeutics (LENZ), Agilent (A) and Hims & Hers Health (HIMS) with neutral ratings, indicating ...

Analysts Are Neutral on These Healthcare Stocks: LENZ Therapeutics (LENZ), Agilent (A)

Hims & Hers Health ($HIMS) still has significant upside potential, but the risks are equally real. That is what makes the stock one of the more int...

Hims & Hers (HIMS) Stock Still Has Upside, but Risks Persist

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS) and Tarsus Pharmaceutica...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS) and Tarsus Pharmaceuticals (TARS)

Hims & Hers Health ( ($HIMS) ) has provided an announcement. On July 1, 2026, XeCare LLC and Apostrophe Pharmacy LLC, subsidiaries of Hims & Hers H...

Hims & Hers Establishes New $400 Million Receivables Facility

Shares of Hims & Hers ($HIMS) rose in pre-market trading after receiving a new Street-high price target of $40. Canaccord Genuity analyst Maria Rip...

HIMS Stock Jumps after Canaccord Raises Price Target to Street-High of $40

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Oruka Therapeutics (ORKA) and Hims &...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HIMS	$29.32	-3.04%	12.75M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HIMS	$29.32	-3.0%	12.75M
3
4
5
6

HIMS

HIMS

Get Hims & Hers Health Inc. Class A Data in Excel

Get Hims & Hers Health Inc. Class A Data in Excel